Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Positive 57.3%

Neg 0% Neu 0% Pos 57.3%

Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.